Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Random

[1]  J. Hines,et al.  In-depth Critical Analysis of Complications Following Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion. , 2017, European urology focus.

[2]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[3]  Geoffrey E. Wile,et al.  Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines , 2016 .

[4]  Geoffrey E. Wile,et al.  NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  D. Lamm,et al.  Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Witjes,et al.  Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. , 2016, European urology.

[7]  B. Lamb,et al.  Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. , 2016, Cancer treatment reviews.

[8]  L. Collette,et al.  EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. , 2016, European urology.

[9]  S. Curley,et al.  Radiofrequency treatment alters cancer cell phenotype , 2015, Scientific Reports.

[10]  S. Groshen,et al.  Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. , 2014, Urology.

[11]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[12]  Ofer Nativ,et al.  The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. , 2011, European urology.

[13]  Andrea Salonia,et al.  Long‐term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‐C alone as adjuvant treatment for non‐muscle‐invasive bladder cancer (NMIBC) , 2011, BJU international.

[14]  Sanjay G. Patel,et al.  Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. , 2010, The Journal of urology.

[15]  Choung-Soo Kim,et al.  Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer , 2009, World Journal of Urology.

[16]  M. Parmar,et al.  A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. , 2007, The Journal of urology.

[17]  J. Witjes,et al.  Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. , 2005, The Journal of urology.

[18]  L. Kiemeney,et al.  Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. , 2004, European urology.

[19]  A. Salonia,et al.  Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Navarra,et al.  Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. , 2003, The Journal of urology.

[21]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[22]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[23]  R. Bahnson,et al.  EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .

[24]  R. Bahnson,et al.  Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. , 2000, The Journal of urology.

[25]  P. Rigatti,et al.  A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. , 1995, The Journal of urology.

[26]  P. Rigatti,et al.  Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. , 1991, European urology.

[27]  W. Catalona,et al.  Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. , 1990, The Journal of urology.